Epstein Secrets

led in Feb (unchanged from Jan vs estimate 40.6%) Marks & Spencer gains the most in six months as sales fall less than estimated (trading 45.47%) Novartis asks EU regulators to approve the Prexige pain pill that was pulled off the market 4 years ago German factory orders climb almost 5x faster than es

Research: Cannacord upgrades BARC.LN, DB upgrades BOS3.GR & initiates SUNS (buy), Bofa downgrades WRB Key Research: Piper upgrades URBN/WTSLA/ZUM2, Baird upgrades FMO & initiates JMF, Opco upgrades BRCM Key Research: Wunderlich downgrades CVLT & upgrades CMO, CS upgrades AXA, Kaufman reinstates EBAY

close). And now Novartis & GSK have announced a major series of transactions: creating new consumer-health venture (GSK 63.5% controlling interest), Novartis agrees to buy GSK's oncology unit for as much as $16B, Novartis to sell vaccines unit to Glaxo for $7.1B, Novartis to sell Animal Health unit to El

uy) and cuts DFRG • Roth initiates GSVC (buy), BMO upgrades HD, B. Riley initiates IMMR (buy) • Evercore upgrades INTU, Steme initiates SYNA (buy), Baird initiates GLRI (op) Europe Key Research: • Bofa initiates PETS LN/SHF SJ (buy) & upgrades ETE GA and RMG LN (buy) • Cantor initiates SRSP LN (buy)

margins below, tweaking FY sales higher (trading +1.8%) • Electrolux June AHAM6 +9%, overall good but freezer and aircon below (trading +0.30%) • Novartis O2 net income/revs/core EPS inline, raises FY sales and profit outlook (trading -1.5%) • Handelsbanken Q2 broadly inline, net income ahead, fee inc

ANH & initiates BXMT (buy), Evercore initiates GOGO (ow) ••• Miller Tabak initiates AREX/FANG (buys), KBW upgrades TAYC/MBFI ••• FBR upgrades ADBE, Baird upgrades BWA, Canaccord downgrades GSS (sell) ••• Raja downgrades ININ, BMO cuts PKG, Williams Capital cuts NVE Europe Key Research: • CS downgrad